Iradimed Other Non Cash Items from 2010 to 2024

IRMD Stock  USD 54.21  0.14  0.26%   
Iradimed's Other Non Cash Items is decreasing over the years with very volatile fluctuation. Other Non Cash Items is expected to dwindle to about 382.2 K. During the period from 2010 to 2024 Iradimed Other Non Cash Items annual values regression line had geometric mean of  184,026 and mean square error of 23311122022.3 T. View All Fundamentals
 
Other Non Cash Items  
First Reported
2013-09-30
Previous Quarter
-246.3 K
Current Value
2.9 M
Quarterly Volatility
92.7 B
 
Yuan Drop
 
Covid
Check Iradimed financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Iradimed's main balance sheet or income statement drivers, such as Interest Expense of 702.6 K, Selling General Administrative of 9.3 M or Selling And Marketing Expenses of 7.8 M, as well as many indicators such as Price To Sales Ratio of 9.61, Dividend Yield of 0.0316 or PTB Ratio of 10.29. Iradimed financial statements analysis is a perfect complement when working with Iradimed Valuation or Volatility modules.
  
Check out the analysis of Iradimed Correlation against competitors.

Latest Iradimed's Other Non Cash Items Growth Pattern

Below is the plot of the Other Non Cash Items of Iradimed Co over the last few years. It is Iradimed's Other Non Cash Items historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Iradimed's overall financial position and show how it may be relating to other accounts over time.
Other Non Cash Items10 Years Trend
Very volatile
   Other Non Cash Items   
       Timeline  

Iradimed Other Non Cash Items Regression Statistics

Arithmetic Mean38,060,613,099
Geometric Mean184,026
Coefficient Of Variation387.30
Mean Deviation71,046,529,884
Median119,044
Standard Deviation147,408,228,775
Sample Variance21729185910.6T
Range570.9B
R-Value(0.06)
Mean Square Error23311122022.3T
R-Squared0
Significance0.83
Slope(2,038,921,685)
Total Sum of Squares304208602748T

Iradimed Other Non Cash Items History

2024382.2 K
2023402.3 K
2022148.7 K
2021119 K
2020-70.1 K
201968.7 K
2018155.7 K

About Iradimed Financial Statements

Iradimed stakeholders use historical fundamental indicators, such as Iradimed's Other Non Cash Items, to determine how well the company is positioned to perform in the future. Although Iradimed investors may analyze each financial statement separately, they are all interrelated. For example, changes in Iradimed's assets and liabilities are reflected in the revenues and expenses on Iradimed's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Iradimed Co. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Non Cash Items402.3 K382.2 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Iradimed is a strong investment it is important to analyze Iradimed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Iradimed's future performance. For an informed investment choice regarding Iradimed Stock, refer to the following important reports:
Check out the analysis of Iradimed Correlation against competitors.
You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iradimed. If investors know Iradimed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iradimed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0)
Dividend Share
0.45
Earnings Share
1.46
Revenue Per Share
5.635
Quarterly Revenue Growth
0.11
The market value of Iradimed is measured differently than its book value, which is the value of Iradimed that is recorded on the company's balance sheet. Investors also form their own opinion of Iradimed's value that differs from its market value or its book value, called intrinsic value, which is Iradimed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iradimed's market value can be influenced by many factors that don't directly affect Iradimed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iradimed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Iradimed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iradimed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.